<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210961</url>
  </required_header>
  <id_info>
    <org_study_id>C2501001</org_study_id>
    <nct_id>NCT03210961</nct_id>
  </id_info>
  <brief_title>A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis</brief_title>
  <official_title>A PHASE 1, WITHIN COHORT, RANDOMIZED, DOUBLE BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06826647 IN HEALTHY SUBJECTS AND SUBJECTS WITH PLAQUE PSORIASIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and
      pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2017</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">January 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Combination single and multiple ascending dose design. Cohorts of participants are assigned to receive interventions based on acceptable safety, tolerability, and pharmacokinetics of previous dose cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period)</measure>
    <time_frame>Baseline up to Day 8</time_frame>
    <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure [BP] and supine pulse rate [PR]) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Multiple Ascending Dose [MAD] Period)</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</measure>
    <time_frame>Baseline up to Day 56</time_frame>
    <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (SAD Period)</measure>
    <time_frame>Baseline up to Day 8</time_frame>
    <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (MAD Period)</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</measure>
    <time_frame>Baseline up to Day 56</time_frame>
    <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-Specified Criteria (SAD Period)</measure>
    <time_frame>Baseline up to Day 8</time_frame>
    <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ECG Data Meeting Pre-Specified Criteria (MAD Period)</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ECG Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</measure>
    <time_frame>Baseline up to Day 56</time_frame>
    <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Who Withdrew Due to Adverse Events (AEs) (SAD Period)</measure>
    <time_frame>Baseline up to Day 8</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.
PBO SAD cohorts = [PBO SAD (3mg, 10mg)] cohorts + [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (MAD Period)</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (Psoriasis Cohorts)</measure>
    <time_frame>Baseline up to Day 84</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities (SAD Period)</measure>
    <time_frame>Baseline up to Day 8</time_frame>
    <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters for laboratory abnormalities evaluation included: erythrocyte mean corpuscular volume (Ery. MCV), erythrocyte mean corpuscular hemoglobin (Ery. MCH), reticulocytes/erythrocytes (%), limphocytes, eosinophils, bilirubin, aspartate aminotransferase (AST), urate, high-density lipoproteins (HDL) cholesterol, low-density lipoproteins (LDL) cholesterol, triglycerides, cholesterol, ketones, nitrite, leukocyte esterase, epithelial cells, urinalysis-bacteria.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities (MAD Period)</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: Ery. MCV &lt;0.9 × LLN, Ery. Mean corpuscular hemoglobin (Ery. MCH) &lt;0.9 × LLN or &gt;1.1 ULN, reticulocytes/erythrocytes (%) &gt;1.5 × ULN, lymphocytes &lt;0.8 × LLN or &gt;1.2 × ULN, neutrophils &lt;0.8 × LLN, eosinophils &gt;1.2 × ULN, bilirubin &gt;1.5 × ULN, urate &gt;1.2 × ULN, HDL cholesterol &lt;0.8 × LLN, LDL cholesterol &gt;1.2 × ULN, triglycerides &gt;1.3 × ULN, bicarbonate &gt;1.1 × ULN, cholesterol &gt;1.3 × ULN, urine glucose ≥1, urine hemoglobin ≥1, nitrite ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-casts &gt;1/LPF, urinalysis-bacteria &gt;20/HPF, urine 24 hours creatinine &gt;1.1 × ULN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities (Psoriasis Cohorts)</measure>
    <time_frame>Baseline up to Day 56</time_frame>
    <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: reticulocytes/erythrocytes (%) &gt;1.5 × ULN, lymphocytes &lt;0.8 × LLN, neutrophils &lt;0.8 × LLN or &gt;1.2 × ULN, eosinophils &gt;1.2 × ULN, bilirubin &gt;1.5 × ULN, alanine aminotransferase (ALT) &gt;3.0 × ULN, creatinine &gt;1.3 × ULN, urate &gt;1.2 × ULN, HDL cholesterol &lt;0.8 × LLN, LDL cholesterol &gt;1.2 × ULN, triglycerides &gt;1.3 × ULN, potassium &gt;1.1 × ULN, bicarbonate &gt;1.1 × ULN, glucose &lt;0.6 × LLN or &gt;1.5 × ULN, Creatine Kinase (CK) &gt;2.0 × ULN, cholesterol &gt;1.3 × ULN, urine glucose ≥1, ketones ≥1, urine hemoglobin ≥1, urine bilirubin ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-bacteria/HPF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 24 Hour Creatinine Clearance From Day -1 on Day 10 (MAD Period)</measure>
    <time_frame>Day -1 and Day 10</time_frame>
    <description>Change in 24-hour creatinine clearance at Day 10 from Day -1 (baseline) during the MAD was presented by treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary: Dose Normalized AUCinf (AUCinf[dn]) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf). AUCinf(dn) = AUCinf / dose. Dose normalized AUC values of PF-06826647 was plotted against dose and included individual participant values and the geometric means for each dose. These plots were used to help understand the relationship between the plasma PK parameters and dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Profile From Time 0 to 24 Hours (AUC24) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>AUC24 was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>AUClast was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized AUClast (AUClast[dn]) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>AUClast(dn) = AUClast / dose. Dose normalized AUC values of PF-06826647 were plotted against dose and included individual participant values and the geometric means for each dose. These plots was used to help understand the relationship between the plasma PK parameters and dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized Cmax (Cmax[dn]) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Cmax (Tmax) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life ((t½) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) (SAD Period)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
    <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Profile Over the Dosing Interval τ (AUCτ) (MAD Period Day 1)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Normalized AUCτ (AUCτ[dn]) (MAD Period Day 1)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.
AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (MAD Period Day 1)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(dn) (MAD Period Day 1)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (MAD Period Day 1)</measure>
    <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ(dn) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.
AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(dn) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration at Steady State (Cav) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Cav = AUCτ,ss / τ, where ss means 'at steady state', and where the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Cav was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lowest Concentration Observed During the Dosing Interval τ (Cmin) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Cmin was observed directly from data. It was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life ((t½) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose</time_frame>
    <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose</time_frame>
    <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Trough Ratio (PTR) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>PTR = Cmax,ss / Cmin,ss, where ss means 'at steady state'. It was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio Based on AUC (Rac) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Rac = AUCτ,ss / AUCτ,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac = AUCτ(Day 10) / AUCτ(Day 1). Rac was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Accumulation Ratio Based on Cmax (Rac,Cmax) (MAD Period Day 10)</measure>
    <time_frame>Days 1 and 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Rac,Cmax = Cmax,ss / Cmax,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac,Cmax = Cmax(Day10) / Cmax(Day 1). Rac,Cmax was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount of Drug Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ = Sum of [urine concentration * sample volume] for each collection interval. Aer was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Dose Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ%) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ% = Aeτ / Dose * 100. Aeτ%was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (Clr) (MAD Period Day 10)</measure>
    <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
    <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aeτ) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCτ), where dosing interval is 24 hours for QD dosing and 12 hours for BID dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>AUCτ was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ(dn) (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(dn) (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>Cav = AUCτ,ss / τ, where ss means 'at steady state'. Cav was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>Cmin was observed directly from data. It was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life ((t½) (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose</time_frame>
    <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose</time_frame>
    <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTR (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>PTR = Cmax,ss / Cmin,ss, it was summarized by dosing regimen and period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (Psoriasis Cohorts)</measure>
    <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
    <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 28</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section*area score*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>PF-06826647 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06826647 oral suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oral solution/suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 tablet</intervention_name>
    <description>PF-06826647 tablet for oral administration</description>
    <arm_group_label>PF-06826647 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 oral suspension</intervention_name>
    <description>PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)</description>
    <arm_group_label>PF-06826647 oral suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo oral solution/suspension</intervention_name>
    <description>placebo oral solution for the single ascending dose, first cohort only</description>
    <arm_group_label>Placebo oral solution/suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Matching placebo tablet</description>
    <arm_group_label>Placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Healthy Participants:

        Inclusion Criteria:

          -  Healthy male subjects between ages of 18-55 years

          -  Healthy female subjects of non-childbearing potential between the ages of 18-55 years

          -  Body Mass Index (BMI) of 17.5 to 30.5kg/m2; and a total body weight &gt;50kg (110lbs).

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

          -  (Optional) Japanese subjects who have four Japanese biologic grandparents born in
             Japan

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential

          -  Fertile male subjects who are unwilling or unable to use a highly effective method of
             contraception as outlined in this protocol for the duration of the study and for at
             least 28 days after the last dose of investigational product

          -  Have a clinically significant infection currently or within 6 months of first dose of
             study drug

        Psoriasis Participants:

        Inclusion Criteria:

          -  Healthy male subjects between ages of 18-65 years

          -  Healthy female subjects of non-childbearing potential between the ages of 18-65 years

          -  Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose

          -  Have plaque-type psoriasis covering at least 15% of total body surface area (BSA) at
             Day-1(prior to randomization in the study

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis (TB)

        Exclusion Criteria:

          -  Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular
             psoriasis

          -  Have a clinically significant infection currently or within 6 months of first dose of
             study drug, or a history of chronic or recurrent infectious disease

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential

          -  Fertile male subjects who are unwilling or unable to use a highly effective method of
             contraception as outlined in this protocol for the duration of the study and for at
             least 28 days after the last dose of investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C2501001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <results_first_submitted>January 13, 2020</results_first_submitted>
  <results_first_submitted_qc>March 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2020</results_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03210961/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03210961/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 208 potential participants were screened after signing an informed consent form, of whom 109 participants were randomized to receive study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (PBO) SAD (3 Milligrams [mg], 10 mg)</title>
          <description>During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, or 10 mg single dose (SD) cohort in fasted state.</description>
        </group>
        <group group_id="P2">
          <title>PBO SAD Followed by (-&gt;) PBO QD MAD</title>
          <description>During SAD period (Period 1), healthy participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg SD cohort, respectively, in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In MAD period (Period 2), these participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg once daily (QD) cohort, respectively, for 10 days with standard meal.</description>
        </group>
        <group group_id="P3">
          <title>PBO QD MAD Japanese Cohort (JP)</title>
          <description>During the MAD period (Period 2), Japanese healthy participants received placebo matching PF-06826647 400 mg QD MAD JP cohort with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="P4">
          <title>PBO Twice Daily (BID)</title>
          <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
        </group>
        <group group_id="P5">
          <title>PF-06826647 3 mg SAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state. SAD period duration was 8 days.</description>
        </group>
        <group group_id="P6">
          <title>PF-06826647 10 mg SAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state. SAD period duration was 8 days.</description>
        </group>
        <group group_id="P7">
          <title>PF-06826647 30 mg SAD -&gt; 30 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="P8">
          <title>PF-06826647 100 mg SAD -&gt; 100 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants 4 received PF-06826647 100 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="P9">
          <title>PF-06826647 400 mg SAD -&gt; 400 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="P10">
          <title>PF-06826647 1600 mg SAD -&gt; 1200 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="P11">
          <title>PF-06826647 200 mg BID</title>
          <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="P12">
          <title>PF-06826647 400 mg QD MAD JP</title>
          <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="P13">
          <title>PBO QD Psoriasis Cohort (PSO)</title>
          <description>In the psoriasis placebo cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD cohort, respectively, for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.</description>
        </group>
        <group group_id="P14">
          <title>PF-06826647 400 mg QD PSO</title>
          <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.</description>
        </group>
        <group group_id="P15">
          <title>PF-06826647 100 mg QD PSO</title>
          <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="14"/>
                <participants group_id="P14" count="15"/>
                <participants group_id="P15" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="12"/>
                <participants group_id="P14" count="11"/>
                <participants group_id="P15" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="4"/>
                <participants group_id="P15" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Longer Meets Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (PBO) SAD (3 mg, 10 mg)</title>
          <description>During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, or 10 mg single dose (SD) cohort in fasted state.</description>
        </group>
        <group group_id="B2">
          <title>PBO SAD Followed by (-&gt;) PBO QD MAD</title>
          <description>During SAD period (Period 1), healthy participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg SD cohort, respectively, in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In MAD period (Period 2), these participants received placebo matching PF-06826647 30, 100, 400, or 1600 mg once daily (QD) cohort, respectively, for 10 days with standard meal.</description>
        </group>
        <group group_id="B3">
          <title>PBO QD MAD Japanese Cohort (JP)</title>
          <description>During the MAD period (Period 2), Japanese healthy participants received placebo matching PF-06826647 400 mg QD MAD JP cohort with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="B4">
          <title>PBO BID</title>
          <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
        </group>
        <group group_id="B5">
          <title>PF-06826647 3 mg SAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state. SAD period duration was 8 days.</description>
        </group>
        <group group_id="B6">
          <title>PF-06826647 10 mg SAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state. SAD period duration was 8 days.</description>
        </group>
        <group group_id="B7">
          <title>PF-06826647 30 mg SAD -&gt; 30 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="B8">
          <title>PF-06826647 100 mg SAD -&gt; 100 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants 4 received PF-06826647 100 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="B9">
          <title>PF-06826647 400 mg SAD -&gt; 400 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="B10">
          <title>PF-06826647 1600 mg SAD -&gt; 1200 mg QD MAD</title>
          <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state. At least 14 days separated the beginning of the SAD and MAD periods. In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal. SAD period duration was 8 days and MAD period duration was 28 days.</description>
        </group>
        <group group_id="B11">
          <title>PF-06826647 200 mg BID</title>
          <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="B12">
          <title>PF-06826647 400 mg QD MAD JP</title>
          <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="B13">
          <title>PBO QD Psoriasis Cohort (PSO)</title>
          <description>In the psoriasis placebo cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD cohort, respectively, for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.</description>
        </group>
        <group group_id="B14">
          <title>PF-06826647 400 mg QD PSO</title>
          <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.</description>
        </group>
        <group group_id="B15">
          <title>PF-06826647 100 mg QD PSO</title>
          <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohorts duration was 84 days, safety and AE evaluations lasted up to Day 84, while vital signs, physical, and laboratory abnormality evaluations lasted up to Day 56.</description>
        </group>
        <group group_id="B16">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="7"/>
            <count group_id="B12" value="5"/>
            <count group_id="B13" value="14"/>
            <count group_id="B14" value="15"/>
            <count group_id="B15" value="11"/>
            <count group_id="B16" value="109"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.5" spread="12.23"/>
                    <measurement group_id="B2" value="42.2" spread="10.84"/>
                    <measurement group_id="B3" value="34.0" spread="NA">only 1 participant in this cohort</measurement>
                    <measurement group_id="B4" value="32.5" spread="4.95"/>
                    <measurement group_id="B5" value="44.3" spread="11.47"/>
                    <measurement group_id="B6" value="40.2" spread="10.30"/>
                    <measurement group_id="B7" value="40.5" spread="11.64"/>
                    <measurement group_id="B8" value="36.9" spread="7.40"/>
                    <measurement group_id="B9" value="37.5" spread="8.23"/>
                    <measurement group_id="B10" value="31.2" spread="5.00"/>
                    <measurement group_id="B11" value="37.4" spread="9.27"/>
                    <measurement group_id="B12" value="39.8" spread="5.40"/>
                    <measurement group_id="B13" value="38.3" spread="13.25"/>
                    <measurement group_id="B14" value="40.9" spread="11.62"/>
                    <measurement group_id="B15" value="39.0" spread="13.39"/>
                    <measurement group_id="B16" value="39.0" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="14"/>
                    <measurement group_id="B14" value="15"/>
                    <measurement group_id="B15" value="11"/>
                    <measurement group_id="B16" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="7"/>
                    <measurement group_id="B14" value="11"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="2"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="11"/>
                    <measurement group_id="B14" value="9"/>
                    <measurement group_id="B15" value="11"/>
                    <measurement group_id="B16" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period)</title>
        <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure [BP] and supine pulse rate [PR]) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
        <time_frame>Baseline up to Day 8</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO SAD</title>
            <description>During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in [PBO SAD (3mg, 10mg)] cohorts + participants in [PBO SAD -&gt; PBO QD] cohorts.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period)</title>
          <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure [BP] and supine pulse rate [PR]) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine diastolic BP Value &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP Change (Chg) ≥20 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP Chg ≥20 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate Value &lt;40 beats per minute (bpm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate Value &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Value &lt;90mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Chg ≥30 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Chg ≥30mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Multiple Ascending Dose [MAD] Period)</title>
        <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.</description>
        <time_frame>Baseline up to Day 28</time_frame>
        <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD MAD (JP PBO Included)</title>
            <description>This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PBO BID</title>
            <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 200 mg BID</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Multiple Ascending Dose [MAD] Period)</title>
          <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.</description>
          <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine diastolic BP Value &lt; 50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP Chg ≥ 20 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP Chg ≥ 20 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate Value &lt; 40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate Value &gt; 120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic blood pressure Value &lt; 90 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Chg ≥ 30 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Chg ≥ 30 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</title>
        <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.</description>
        <time_frame>Baseline up to Day 56</time_frame>
        <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD PSO</title>
            <description>In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</title>
          <description>Maximum absolute values and changes from baseline for vital signs (for supine systolic/diastolic blood pressure and supine pulse rate) were summarized descriptively by treatment. Numbers of participants meeting the categorical criteria were provided.</description>
          <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine diastolic blood pressure Value &lt; 50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP Chg ≥ 20 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP Chg ≥ 20 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate Value &lt; 40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine pulse rate Value &gt; 120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Value &lt; 90 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Chg ≥ 30 mmHg increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP Chg ≥ 30 mmHg decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (SAD Period)</title>
        <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
        <time_frame>Baseline up to Day 8</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO SAD</title>
            <description>During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in [PBO SAD (3mg, 10mg)] cohorts + participants in [PBO SAD -&gt; PBO QD] cohorts.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (SAD Period)</title>
          <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ears</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>general appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>head</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>heart</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lungs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (MAD Period)</title>
        <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.</description>
        <time_frame>Baseline up to Day 28</time_frame>
        <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD MAD</title>
            <description>This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PBO BID</title>
            <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 200 mg BID</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (MAD Period)</title>
          <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.</description>
          <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ears</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>general appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>head</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>heart</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lungs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</title>
        <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.</description>
        <time_frame>Baseline up to Day 56</time_frame>
        <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD PSO</title>
            <description>In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Physical Examination Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</title>
          <description>Physical examinations were conducted by a physician, trained physician assistant, or nurse practitioner as acceptable according to local regulation. A full physical examination included head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.</description>
          <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ears at screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ears at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eyes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>general appearance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>head</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>heart</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lungs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>musculoskeletal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neurological</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-Specified Criteria (SAD Period)</title>
        <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
        <time_frame>Baseline up to Day 8</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO SAD</title>
            <description>During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in [PBO SAD (3mg, 10mg)] cohorts + participants in [PBO SAD -&gt; PBO QD] cohorts.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-Specified Criteria (SAD Period)</title>
          <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR maximum absolute value ≥300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR maximum increase from baseline ≥25/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS maximum absolute value ≥140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS maximum increase from baseline ≥50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥450 and &lt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥480 and &lt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum increase ≥30 and &lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum increase from baseline ≥60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ECG Data Meeting Pre-Specified Criteria (MAD Period)</title>
        <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.</description>
        <time_frame>Baseline up to Day 28</time_frame>
        <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD MAD</title>
            <description>This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PBO BID</title>
            <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 200 mg BID</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ECG Data Meeting Pre-Specified Criteria (MAD Period)</title>
          <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.</description>
          <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR maximum absolute value ≥300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR maximum increase from baseline ≥25/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS maximum absolute value ≥140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS maximum increase from baseline ≥50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥450 and &lt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥480 and &lt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum increase ≥30 and &lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum increase from baseline ≥60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With ECG Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</title>
        <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.</description>
        <time_frame>Baseline up to Day 56</time_frame>
        <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD PSO</title>
            <description>In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ECG Data Meeting Pre-Specified Criteria (Psoriasis Cohorts)</title>
          <description>ECG endpoints and changes from baseline (QTcF, PR and QRS) were summarized descriptively by cohort and treatment using pre-defined categories. Numbers of participants meeting the categorical criteria were provided. All planned and unplanned post-dose time points were counted in these categorical summaries. Categorical summarization criteria for ECG were as follows: 1) QTcF maximum absolute value ≥450 and &lt;480 millisecond (msec), ≥480 and &lt;500 msec. ≥500 msec; 2) QTcF maximum increase ≥30 and &lt;60 msec, ≥60 msec; 3) PR maximum absolute value ≥300 msec; 4) PR maximum increases from baseline ≥25% if baseline &gt;200 msec, ≥50% if baseline ≤200 msec; 5) QRS maximum absolute value ≥140 msec; 6) QRS maximum increase from baseline ≥50%.</description>
          <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR maximum absolute value ≥300 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR maximum increase from baseline ≥25/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS maximum absolute value ≥140 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS maximum increase from baseline ≥50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥450 and &lt;480 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥480 and &lt;500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum absolute value ≥500 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum increase ≥30 and &lt;60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF maximum increase from baseline ≥60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Who Withdrew Due to Adverse Events (AEs) (SAD Period)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.
PBO SAD cohorts = [PBO SAD (3mg, 10mg)] cohorts + [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
        <time_frame>Baseline up to Day 8</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO SAD</title>
            <description>During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in [PBO SAD (3mg, 10mg)] cohorts + participants in [PBO SAD -&gt; PBO QD] cohorts.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Who Withdrew Due to Adverse Events (AEs) (SAD Period)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.
PBO SAD cohorts = [PBO SAD (3mg, 10mg)] cohorts + [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants withdrew due to AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants withdrew due to AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (MAD Period)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.</description>
        <time_frame>Baseline up to Day 28</time_frame>
        <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD MAD</title>
            <description>This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PBO BID</title>
            <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 200 mg BID</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (MAD Period)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.</description>
          <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants withdrew due to AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants withdrew due to AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (Psoriasis Cohorts)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.</description>
        <time_frame>Baseline up to Day 84</time_frame>
        <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD PSO</title>
            <description>In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs, SAEs, and Who Withdrew Due to AEs (Psoriasis Cohorts)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. All events occurring following start of the treatment or increasing in severity were counted as treatment emergent. Events that occurred in a non-treatment period (eg, washout or follow-up) were counted as treatment emergent and attributed to the previous treatment taken. For each event, the investigator pursued and obtained adequate information both to determine the outcome and to assess whether it meets the criteria for classification as an SAE.</description>
          <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with severe AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants withdrew due to AEs (AC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants withdrew due to AEs (TR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities (SAD Period)</title>
        <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters for laboratory abnormalities evaluation included: erythrocyte mean corpuscular volume (Ery. MCV), erythrocyte mean corpuscular hemoglobin (Ery. MCH), reticulocytes/erythrocytes (%), limphocytes, eosinophils, bilirubin, aspartate aminotransferase (AST), urate, high-density lipoproteins (HDL) cholesterol, low-density lipoproteins (LDL) cholesterol, triglycerides, cholesterol, ketones, nitrite, leukocyte esterase, epithelial cells, urinalysis-bacteria.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
        <time_frame>Baseline up to Day 8</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO SAD</title>
            <description>During the SAD period (Period 1), healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg single dose (SD) cohort in fasted state. Participants in PBO SAD cohorts = participants in [PBO SAD (3mg, 10mg)] cohorts + participants in [PBO SAD -&gt; PBO QD] cohorts.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities (SAD Period)</title>
          <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters for laboratory abnormalities evaluation included: erythrocyte mean corpuscular volume (Ery. MCV), erythrocyte mean corpuscular hemoglobin (Ery. MCH), reticulocytes/erythrocytes (%), limphocytes, eosinophils, bilirubin, aspartate aminotransferase (AST), urate, high-density lipoproteins (HDL) cholesterol, low-density lipoproteins (LDL) cholesterol, triglycerides, cholesterol, ketones, nitrite, leukocyte esterase, epithelial cells, urinalysis-bacteria.
Number of participants in PBO SAD cohorts = number of participants in [PBO SAD (3mg, 10mg)] cohorts + number of participants in [PBO SAD -&gt; PBO QD MAD] cohorts.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the safety parameters in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ery. MCV (femtoliters [fL]) &lt;0.9 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. MCH (picograms [pg]) &lt;0.9 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes/erythrocytes (%) &gt;1.5 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limphocytes (10^3/mm^3) &lt;0.8 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (10^3/mm^3) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (mg/dL) &gt;1.5 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (U/L) &gt;3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate (mg/dL) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol (mg/dL) &lt;0.8 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (mg/dL) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (mg/dL) &gt;1.3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol (mg/dL) &gt;1.3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epithelial cells (/LPF) ≥6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis-bacteria (/HPF) ≥20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities (MAD Period)</title>
        <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: Ery. MCV &lt;0.9 × LLN, Ery. Mean corpuscular hemoglobin (Ery. MCH) &lt;0.9 × LLN or &gt;1.1 ULN, reticulocytes/erythrocytes (%) &gt;1.5 × ULN, lymphocytes &lt;0.8 × LLN or &gt;1.2 × ULN, neutrophils &lt;0.8 × LLN, eosinophils &gt;1.2 × ULN, bilirubin &gt;1.5 × ULN, urate &gt;1.2 × ULN, HDL cholesterol &lt;0.8 × LLN, LDL cholesterol &gt;1.2 × ULN, triglycerides &gt;1.3 × ULN, bicarbonate &gt;1.1 × ULN, cholesterol &gt;1.3 × ULN, urine glucose ≥1, urine hemoglobin ≥1, nitrite ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-casts &gt;1/LPF, urinalysis-bacteria &gt;20/HPF, urine 24 hours creatinine &gt;1.1 × ULN.</description>
        <time_frame>Baseline up to Day 28</time_frame>
        <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD MAD</title>
            <description>This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PBO BID</title>
            <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 200 mg BID</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities (MAD Period)</title>
          <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: Ery. MCV &lt;0.9 × LLN, Ery. Mean corpuscular hemoglobin (Ery. MCH) &lt;0.9 × LLN or &gt;1.1 ULN, reticulocytes/erythrocytes (%) &gt;1.5 × ULN, lymphocytes &lt;0.8 × LLN or &gt;1.2 × ULN, neutrophils &lt;0.8 × LLN, eosinophils &gt;1.2 × ULN, bilirubin &gt;1.5 × ULN, urate &gt;1.2 × ULN, HDL cholesterol &lt;0.8 × LLN, LDL cholesterol &gt;1.2 × ULN, triglycerides &gt;1.3 × ULN, bicarbonate &gt;1.1 × ULN, cholesterol &gt;1.3 × ULN, urine glucose ≥1, urine hemoglobin ≥1, nitrite ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-casts &gt;1/LPF, urinalysis-bacteria &gt;20/HPF, urine 24 hours creatinine &gt;1.1 × ULN.</description>
          <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ery. MCV (fL) &lt;0.9 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. MCH (pg) &lt;0.9 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ery. MCH (pg) &gt;1.1 × ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes/erythrocytes (%) &gt;1.5 × ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (10^3/mm^3) &lt;0.8 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (10^3/mm^3) &gt;1.2 × ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (10^3/mm^3) &lt;0.8 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (10^3/mm^3) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (mg/dL) &gt;1.5 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate (mg/dL) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol (mg/dL) &lt;0.8 × LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (mg/dL) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (mg/dL) &gt;1.3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mEq/L) &gt;1.1 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (mg/dL) &gt;1.3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine glucose ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine hemoglobin ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nitrite ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epithelial cells (/LPF) ≥6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis-casts (/LPF) &gt;1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis-bacteria (/HPF) &gt;20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine 24 hours creatinine (mg/24 hr) &gt;1.1 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities (Psoriasis Cohorts)</title>
        <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: reticulocytes/erythrocytes (%) &gt;1.5 × ULN, lymphocytes &lt;0.8 × LLN, neutrophils &lt;0.8 × LLN or &gt;1.2 × ULN, eosinophils &gt;1.2 × ULN, bilirubin &gt;1.5 × ULN, alanine aminotransferase (ALT) &gt;3.0 × ULN, creatinine &gt;1.3 × ULN, urate &gt;1.2 × ULN, HDL cholesterol &lt;0.8 × LLN, LDL cholesterol &gt;1.2 × ULN, triglycerides &gt;1.3 × ULN, potassium &gt;1.1 × ULN, bicarbonate &gt;1.1 × ULN, glucose &lt;0.6 × LLN or &gt;1.5 × ULN, Creatine Kinase (CK) &gt;2.0 × ULN, cholesterol &gt;1.3 × ULN, urine glucose ≥1, ketones ≥1, urine hemoglobin ≥1, urine bilirubin ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-bacteria/HPF.</description>
        <time_frame>Baseline up to Day 56</time_frame>
        <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD PSO</title>
            <description>In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities (Psoriasis Cohorts)</title>
          <description>Laboratory data were listed and summarized by treatment in accordance with the sponsor reporting standards. Parameters and corresponding primary criteria for laboratory abnormalities evaluation included: reticulocytes/erythrocytes (%) &gt;1.5 × ULN, lymphocytes &lt;0.8 × LLN, neutrophils &lt;0.8 × LLN or &gt;1.2 × ULN, eosinophils &gt;1.2 × ULN, bilirubin &gt;1.5 × ULN, alanine aminotransferase (ALT) &gt;3.0 × ULN, creatinine &gt;1.3 × ULN, urate &gt;1.2 × ULN, HDL cholesterol &lt;0.8 × LLN, LDL cholesterol &gt;1.2 × ULN, triglycerides &gt;1.3 × ULN, potassium &gt;1.1 × ULN, bicarbonate &gt;1.1 × ULN, glucose &lt;0.6 × LLN or &gt;1.5 × ULN, Creatine Kinase (CK) &gt;2.0 × ULN, cholesterol &gt;1.3 × ULN, urine glucose ≥1, ketones ≥1, urine hemoglobin ≥1, urine bilirubin ≥1, leukocyte esterase ≥1, epithelial cells ≥6/LPF, urinalysis-bacteria/HPF.</description>
          <population>The analysis population included the psoriasis participants who received study treatment and who had the safety parameters in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reticulocytes/erythrocytes (%) &gt;1.5 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (10^3/mm^3) &lt;0.8 x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (10^3/mm^3) &lt;0.8 x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (10^3/mm^3) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (10^3/mm^3) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (mg/dL) &gt;1.5 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (U/L) &gt;3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine (mg/dL) &gt;1.3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate (mg/dL) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol (mg/dL) &lt;0.8 x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (mg/dL) &gt;1.2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (mg/dL) &gt;1.3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (mEq/L) &gt;1.1 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mEq/L) &gt;1.1 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mg/dL) &lt;0.6 x LLN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mg/dL) &gt;1.5 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK (U/L) &gt;2 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol (mg/dL) &gt;1.3 x ULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine glucose ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine hemoglobin ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine bilirubin ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte esterase ≥1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epithelial cells (/LPF) ≥6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinalysis-bacteria (/HPF) &gt;20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in 24 Hour Creatinine Clearance From Day -1 on Day 10 (MAD Period)</title>
        <description>Change in 24-hour creatinine clearance at Day 10 from Day -1 (baseline) during the MAD was presented by treatment group.</description>
        <time_frame>Day -1 and Day 10</time_frame>
        <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD MAD</title>
            <description>This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants received placebo matching PF-06826647 30, 100, 400, or 1200 mg once daily (QD) cohort while the Japanese participants received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PBO BID</title>
            <description>During the MAD period (Period 2), healthy participants received placebo matching PF-06826647 200 mg BID cohort with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O7">
            <title>PF-06826647 200 mg BID</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O8">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24 Hour Creatinine Clearance From Day -1 on Day 10 (MAD Period)</title>
          <description>Change in 24-hour creatinine clearance at Day 10 from Day -1 (baseline) during the MAD was presented by treatment group.</description>
          <population>The analysis population included the healthy participants who received study treatment in the MAD Period. The PBO QD MAD sequence is comprised of both non-Japanese and Japanese participants. The non-Japanese participants had completed the SAD period and continued into the MAD period. The Japanese participants took part only in the MAD period.</population>
          <units>milliliters per minute (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.0" spread="98.76"/>
                    <measurement group_id="O2" value="-32.0" spread="NA">One (1) participant was analyzed, so standard deviation did not exist.</measurement>
                    <measurement group_id="O3" value="-62.4" spread="45.10"/>
                    <measurement group_id="O4" value="0.2" spread="65.64"/>
                    <measurement group_id="O5" value="-52.5" spread="56.22"/>
                    <measurement group_id="O6" value="-11.4" spread="58.76"/>
                    <measurement group_id="O7" value="-64.7" spread="36.22"/>
                    <measurement group_id="O8" value="40.2" spread="45.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) (SAD Period)</title>
        <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) (SAD Period)</title>
          <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf).</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>nanograms*hours per mL (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.63" spread="59"/>
                    <measurement group_id="O2" value="369.3" spread="67"/>
                    <measurement group_id="O3" value="848.4" spread="40"/>
                    <measurement group_id="O4" value="1582" spread="42"/>
                    <measurement group_id="O5" value="3056" spread="65"/>
                    <measurement group_id="O6" value="11790" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary: Dose Normalized AUCinf (AUCinf[dn]) (SAD Period)</title>
        <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf). AUCinf(dn) = AUCinf / dose. Dose normalized AUC values of PF-06826647 was plotted against dose and included individual participant values and the geometric means for each dose. These plots were used to help understand the relationship between the plasma PK parameters and dose.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary: Dose Normalized AUCinf (AUCinf[dn]) (SAD Period)</title>
          <description>AUCinf = Area under the plasma concentration versus time curve (AUC) from time 0 (pre-dose) to extrapolated infinite time (0-inf). It is obtained from AUC (0-t) plus AUC (t-inf). AUCinf(dn) = AUCinf / dose. Dose normalized AUC values of PF-06826647 was plotted against dose and included individual participant values and the geometric means for each dose. These plots were used to help understand the relationship between the plasma PK parameters and dose.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.86" spread="59"/>
                    <measurement group_id="O2" value="36.93" spread="67"/>
                    <measurement group_id="O3" value="28.28" spread="41"/>
                    <measurement group_id="O4" value="15.82" spread="42"/>
                    <measurement group_id="O5" value="7.636" spread="65"/>
                    <measurement group_id="O6" value="7.370" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Profile From Time 0 to 24 Hours (AUC24) (SAD Period)</title>
        <description>AUC24 was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Profile From Time 0 to 24 Hours (AUC24) (SAD Period)</title>
          <description>AUC24 was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.10" spread="56"/>
                    <measurement group_id="O2" value="347.8" spread="62"/>
                    <measurement group_id="O3" value="543.2" spread="49"/>
                    <measurement group_id="O4" value="1158" spread="55"/>
                    <measurement group_id="O5" value="2519" spread="67"/>
                    <measurement group_id="O6" value="9318" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) (SAD Period)</title>
        <description>AUClast was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) (SAD Period)</title>
          <description>AUClast was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.25" spread="56"/>
                    <measurement group_id="O2" value="354.8" spread="67"/>
                    <measurement group_id="O3" value="638.5" spread="58"/>
                    <measurement group_id="O4" value="1375" spread="53"/>
                    <measurement group_id="O5" value="2767" spread="65"/>
                    <measurement group_id="O6" value="9921" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized AUClast (AUClast[dn]) (SAD Period)</title>
        <description>AUClast(dn) = AUClast / dose. Dose normalized AUC values of PF-06826647 were plotted against dose and included individual participant values and the geometric means for each dose. These plots was used to help understand the relationship between the plasma PK parameters and dose.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized AUClast (AUClast[dn]) (SAD Period)</title>
          <description>AUClast(dn) = AUClast / dose. Dose normalized AUC values of PF-06826647 were plotted against dose and included individual participant values and the geometric means for each dose. These plots was used to help understand the relationship between the plasma PK parameters and dose.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.40" spread="56"/>
                    <measurement group_id="O2" value="35.48" spread="67"/>
                    <measurement group_id="O3" value="21.28" spread="58"/>
                    <measurement group_id="O4" value="13.75" spread="53"/>
                    <measurement group_id="O5" value="6.919" spread="65"/>
                    <measurement group_id="O6" value="6.200" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) (SAD Period)</title>
        <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) (SAD Period)</title>
          <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.844" spread="38"/>
                    <measurement group_id="O2" value="47.09" spread="35"/>
                    <measurement group_id="O3" value="77.93" spread="34"/>
                    <measurement group_id="O4" value="166.8" spread="55"/>
                    <measurement group_id="O5" value="404.8" spread="62"/>
                    <measurement group_id="O6" value="1218" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized Cmax (Cmax[dn]) (SAD Period)</title>
        <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Cmax (Cmax[dn]) (SAD Period)</title>
          <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
          <population>The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.617" spread="38"/>
                    <measurement group_id="O2" value="4.709" spread="35"/>
                    <measurement group_id="O3" value="2.597" spread="34"/>
                    <measurement group_id="O4" value="1.668" spread="55"/>
                    <measurement group_id="O5" value="1.012" spread="62"/>
                    <measurement group_id="O6" value="0.7618" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Cmax (Tmax) (SAD Period)</title>
        <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Cmax (Tmax) (SAD Period)</title>
          <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
          <population>The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="2.00" lower_limit="0.500" upper_limit="4.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="0.500" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life ((t½) (SAD Period)</title>
        <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life ((t½) (SAD Period)</title>
          <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>hours (hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.620" spread="1.2956"/>
                    <measurement group_id="O2" value="6.032" spread="1.9050"/>
                    <measurement group_id="O3" value="19.69" spread="9.5144"/>
                    <measurement group_id="O4" value="38.77" spread="35.966"/>
                    <measurement group_id="O5" value="16.25" spread="9.3430"/>
                    <measurement group_id="O6" value="22.21" spread="24.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT) (SAD Period)</title>
        <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT) (SAD Period)</title>
          <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
          <population>The analysis population included healthy participants who received the study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>hours (hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.596" spread="26"/>
                    <measurement group_id="O2" value="7.761" spread="30"/>
                    <measurement group_id="O3" value="16.97" spread="43"/>
                    <measurement group_id="O4" value="21.23" spread="81"/>
                    <measurement group_id="O5" value="10.56" spread="36"/>
                    <measurement group_id="O6" value="9.417" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) (SAD Period)</title>
        <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) (SAD Period)</title>
          <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312.1" spread="34"/>
                    <measurement group_id="O2" value="226.1" spread="41"/>
                    <measurement group_id="O3" value="902.9" spread="81"/>
                    <measurement group_id="O4" value="2671" spread="134"/>
                    <measurement group_id="O5" value="2732" spread="128"/>
                    <measurement group_id="O6" value="2877" spread="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) (SAD Period)</title>
        <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24,36,48,72,168 hours post-dose</time_frame>
        <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 3 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 3 mg SD in fasted state.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 10 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 10 mg SD in fasted state.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 30 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 30 mg SD in fasted state.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 100 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 100 mg SD in fasted state.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 400 mg SD in fasted state.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1600 mg SAD</title>
            <description>During the SAD period (Period 1), healthy participants received PF-06826647 1600 mg SD in fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) (SAD Period)</title>
          <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>The analysis population included the healthy participants who received study treatment and who had the PK parameter in the SAD Period. MAD and Psoriasis Cohorts data were not included.</population>
          <units>liters per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.98" spread="59"/>
                    <measurement group_id="O2" value="27.08" spread="67"/>
                    <measurement group_id="O3" value="35.36" spread="41"/>
                    <measurement group_id="O4" value="63.21" spread="42"/>
                    <measurement group_id="O5" value="130.8" spread="65"/>
                    <measurement group_id="O6" value="135.4" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Profile Over the Dosing Interval τ (AUCτ) (MAD Period Day 1)</title>
        <description>AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Profile Over the Dosing Interval τ (AUCτ) (MAD Period Day 1)</title>
          <description>AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.8" spread="25"/>
                    <measurement group_id="O2" value="1803" spread="23"/>
                    <measurement group_id="O3" value="1646" spread="70"/>
                    <measurement group_id="O4" value="4424" spread="67"/>
                    <measurement group_id="O5" value="6038" spread="29"/>
                    <measurement group_id="O6" value="17090" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Normalized AUCτ (AUCτ[dn]) (MAD Period Day 1)</title>
        <description>Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.
AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized AUCτ (AUCτ[dn]) (MAD Period Day 1)</title>
          <description>Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.
AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.10" spread="25"/>
                    <measurement group_id="O2" value="18.03" spread="23"/>
                    <measurement group_id="O3" value="8.229" spread="70"/>
                    <measurement group_id="O4" value="11.07" spread="67"/>
                    <measurement group_id="O5" value="15.10" spread="29"/>
                    <measurement group_id="O6" value="14.23" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (MAD Period Day 1)</title>
        <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (MAD Period Day 1)</title>
          <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.53" spread="24"/>
                    <measurement group_id="O2" value="267.2" spread="20"/>
                    <measurement group_id="O3" value="289.8" spread="67"/>
                    <measurement group_id="O4" value="585.9" spread="33"/>
                    <measurement group_id="O5" value="695.5" spread="19"/>
                    <measurement group_id="O6" value="2023" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax(dn) (MAD Period Day 1)</title>
        <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax(dn) (MAD Period Day 1)</title>
          <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.787" spread="24"/>
                    <measurement group_id="O2" value="2.672" spread="20"/>
                    <measurement group_id="O3" value="1.450" spread="67"/>
                    <measurement group_id="O4" value="1.468" spread="33"/>
                    <measurement group_id="O5" value="1.741" spread="19"/>
                    <measurement group_id="O6" value="1.686" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (MAD Period Day 1)</title>
        <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
        <time_frame>Day 1 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (MAD Period Day 1)</title>
          <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="4.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ (MAD Period Day 10)</title>
        <description>AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ (MAD Period Day 10)</title>
          <description>AUCτ was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval was 24 hours for QD dosing and 12 hours for BID dosing. It was determined by linear/log trapezoidal method.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="752.9" spread="32"/>
                    <measurement group_id="O2" value="1952" spread="33"/>
                    <measurement group_id="O3" value="2010" spread="49"/>
                    <measurement group_id="O4" value="5420" spread="57"/>
                    <measurement group_id="O5" value="7194" spread="20"/>
                    <measurement group_id="O6" value="14890" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ(dn) (MAD Period Day 10)</title>
        <description>Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.
AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ(dn) (MAD Period Day 10)</title>
          <description>Area Under the Plasma Concentration-Time Profile over the Dosing interval τ (AUCτ). Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.
AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.06" spread="32"/>
                    <measurement group_id="O2" value="19.52" spread="33"/>
                    <measurement group_id="O3" value="10.04" spread="49"/>
                    <measurement group_id="O4" value="13.56" spread="57"/>
                    <measurement group_id="O5" value="18.00" spread="19"/>
                    <measurement group_id="O6" value="12.41" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (MAD Period Day 10)</title>
        <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (MAD Period Day 10)</title>
          <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.34" spread="27"/>
                    <measurement group_id="O2" value="263.2" spread="30"/>
                    <measurement group_id="O3" value="339.5" spread="46"/>
                    <measurement group_id="O4" value="667.3" spread="37"/>
                    <measurement group_id="O5" value="887.0" spread="11"/>
                    <measurement group_id="O6" value="1855" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax(dn) (MAD Period Day 10)</title>
        <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax(dn) (MAD Period Day 10)</title>
          <description>Cmax(dn) = Cmax / dose. To assess the relationship between Cmax and dose, dose normalized Cmax was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.844" spread="27"/>
                    <measurement group_id="O2" value="2.632" spread="30"/>
                    <measurement group_id="O3" value="1.701" spread="46"/>
                    <measurement group_id="O4" value="1.669" spread="37"/>
                    <measurement group_id="O5" value="2.220" spread="11"/>
                    <measurement group_id="O6" value="1.547" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (MAD Period Day 10)</title>
        <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (MAD Period Day 10)</title>
          <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="4.00" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Concentration at Steady State (Cav) (MAD Period Day 10)</title>
        <description>Cav = AUCτ,ss / τ, where ss means 'at steady state', and where the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Cav was summarized by dosing regimen and period.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Concentration at Steady State (Cav) (MAD Period Day 10)</title>
          <description>Cav = AUCτ,ss / τ, where ss means 'at steady state', and where the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Cav was summarized by dosing regimen and period.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.36" spread="32"/>
                    <measurement group_id="O2" value="81.28" spread="34"/>
                    <measurement group_id="O3" value="167.6" spread="49"/>
                    <measurement group_id="O4" value="226.0" spread="57"/>
                    <measurement group_id="O5" value="299.7" spread="20"/>
                    <measurement group_id="O6" value="619.9" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lowest Concentration Observed During the Dosing Interval τ (Cmin) (MAD Period Day 10)</title>
        <description>Cmin was observed directly from data. It was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Lowest Concentration Observed During the Dosing Interval τ (Cmin) (MAD Period Day 10)</title>
          <description>Cmin was observed directly from data. It was summarized by dosing regimen and period. Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.273" spread="83"/>
                    <measurement group_id="O2" value="10.40" spread="75"/>
                    <measurement group_id="O3" value="55.01" spread="65"/>
                    <measurement group_id="O4" value="24.77" spread="148"/>
                    <measurement group_id="O5" value="29.50" spread="60"/>
                    <measurement group_id="O6" value="62.26" spread="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life ((t½) (MAD Period Day 10)</title>
        <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life ((t½) (MAD Period Day 10)</title>
          <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>hours (hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.802" spread="5.8142"/>
                    <measurement group_id="O2" value="12.72" spread="12.644"/>
                    <measurement group_id="O3" value="26.93" spread="8.1132"/>
                    <measurement group_id="O4" value="7.500" spread="2.5803"/>
                    <measurement group_id="O5" value="7.433" spread="4.7975"/>
                    <measurement group_id="O6" value="34.33" spread="21.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRT (MAD Period Day 10)</title>
        <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24,48,72,96,168 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>MRT (MAD Period Day 10)</title>
          <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>hours (hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" spread="44"/>
                    <measurement group_id="O2" value="9.872" spread="33"/>
                    <measurement group_id="O3" value="17.14" spread="26"/>
                    <measurement group_id="O4" value="9.622" spread="26"/>
                    <measurement group_id="O5" value="7.996" spread="19"/>
                    <measurement group_id="O6" value="9.165" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Trough Ratio (PTR) (MAD Period Day 10)</title>
        <description>PTR = Cmax,ss / Cmin,ss, where ss means 'at steady state'. It was summarized by dosing regimen and period.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Trough Ratio (PTR) (MAD Period Day 10)</title>
          <description>PTR = Cmax,ss / Cmin,ss, where ss means 'at steady state'. It was summarized by dosing regimen and period.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.61" spread="69"/>
                    <measurement group_id="O2" value="25.31" spread="55"/>
                    <measurement group_id="O3" value="6.951" spread="23"/>
                    <measurement group_id="O4" value="26.92" spread="112"/>
                    <measurement group_id="O5" value="30.09" spread="61"/>
                    <measurement group_id="O6" value="29.76" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Accumulation Ratio Based on AUC (Rac) (MAD Period Day 10)</title>
        <description>Rac = AUCτ,ss / AUCτ,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac = AUCτ(Day 10) / AUCτ(Day 1). Rac was summarized by dosing regimen and period.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Accumulation Ratio Based on AUC (Rac) (MAD Period Day 10)</title>
          <description>Rac = AUCτ,ss / AUCτ,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac = AUCτ(Day 10) / AUCτ(Day 1). Rac was summarized by dosing regimen and period.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.085" spread="8"/>
                    <measurement group_id="O2" value="1.082" spread="21"/>
                    <measurement group_id="O3" value="1.328" spread="52"/>
                    <measurement group_id="O4" value="1.225" spread="39"/>
                    <measurement group_id="O5" value="1.191" spread="24"/>
                    <measurement group_id="O6" value="0.8711" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Observed Accumulation Ratio Based on Cmax (Rac,Cmax) (MAD Period Day 10)</title>
        <description>Rac,Cmax = Cmax,ss / Cmax,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac,Cmax = Cmax(Day10) / Cmax(Day 1). Rac,Cmax was summarized by dosing regimen and period.</description>
        <time_frame>Days 1 and 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Observed Accumulation Ratio Based on Cmax (Rac,Cmax) (MAD Period Day 10)</title>
          <description>Rac,Cmax = Cmax,ss / Cmax,sd, where ss means 'at steady state' and sd 'single dose'. In this study, Rac,Cmax = Cmax(Day10) / Cmax(Day 1). Rac,Cmax was summarized by dosing regimen and period.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9295" spread="22"/>
                    <measurement group_id="O2" value="0.9852" spread="24"/>
                    <measurement group_id="O3" value="1.282" spread="57"/>
                    <measurement group_id="O4" value="1.139" spread="35"/>
                    <measurement group_id="O5" value="1.275" spread="14"/>
                    <measurement group_id="O6" value="0.9176" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F (MAD Period Day 10)</title>
        <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F (MAD Period Day 10)</title>
          <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="433.5" spread="52"/>
                    <measurement group_id="O2" value="643.6" spread="98"/>
                    <measurement group_id="O3" value="3224" spread="90"/>
                    <measurement group_id="O4" value="758.9" spread="93"/>
                    <measurement group_id="O5" value="519.2" spread="67"/>
                    <measurement group_id="O6" value="2944" spread="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F (MAD Period Day 10)</title>
        <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F (MAD Period Day 10)</title>
          <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>liters per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.86" spread="32"/>
                    <measurement group_id="O2" value="51.27" spread="34"/>
                    <measurement group_id="O3" value="99.47" spread="49"/>
                    <measurement group_id="O4" value="73.78" spread="57"/>
                    <measurement group_id="O5" value="55.62" spread="20"/>
                    <measurement group_id="O6" value="80.63" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount of Drug Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ) (MAD Period Day 10)</title>
        <description>Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ = Sum of [urine concentration * sample volume] for each collection interval. Aer was summarized by dosing regimen and period.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount of Drug Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ) (MAD Period Day 10)</title>
          <description>Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ = Sum of [urine concentration * sample volume] for each collection interval. Aer was summarized by dosing regimen and period.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2204" spread="35"/>
                    <measurement group_id="O2" value="1.072" spread="65"/>
                    <measurement group_id="O3" value="2.560" spread="66"/>
                    <measurement group_id="O4" value="3.134" spread="75"/>
                    <measurement group_id="O5" value="2.931" spread="624"/>
                    <measurement group_id="O6" value="14.73" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Dose Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ%) (MAD Period Day 10)</title>
        <description>Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ% = Aeτ / Dose * 100. Aeτ%was summarized by dosing regimen and period.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Dose Recovered Unchanged in Urine From Time 0 to the Dosing Interval τ Hours Post-Dose (Aeτ%) (MAD Period Day 10)</title>
          <description>Dosing interval was the interval τ between administration of doses of drug. In this study, the dosing interval τ was 24 hours for QD dosing and 12 hours for BID dosing. Aeτ% = Aeτ / Dose * 100. Aeτ%was summarized by dosing regimen and period.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>Percentage of Dose</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7344" spread="35"/>
                    <measurement group_id="O2" value="1.072" spread="65"/>
                    <measurement group_id="O3" value="1.280" spread="66"/>
                    <measurement group_id="O4" value="0.7827" spread="75"/>
                    <measurement group_id="O5" value="0.7333" spread="624"/>
                    <measurement group_id="O6" value="1.228" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (Clr) (MAD Period Day 10)</title>
        <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aeτ) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCτ), where dosing interval is 24 hours for QD dosing and 12 hours for BID dosing.</description>
        <time_frame>Day 10 pre-dose, and 0.5,1,2,4,6,8,12,24 hours post-dose</time_frame>
        <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 30 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 30 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 100 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 100 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 200 mg BID MAD</title>
            <description>During the MAD period (Period 2), healthy participants received PF-06826647 200 mg BID for 10 days with standard meal.</description>
          </group>
          <group group_id="O4">
            <title>PF-06826647 400 QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants in Cohort 5 received PF-06826647 400 mg QD for 10 days with standard meal.</description>
          </group>
          <group group_id="O5">
            <title>PF-06826647 400 mg QD MAD JP</title>
            <description>During the MAD period (Period 2), Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
          </group>
          <group group_id="O6">
            <title>PF-06826647 1200 mg QD MAD</title>
            <description>In the MAD period (Period 2), these healthy participants received PF-06826647 1200 mg QD for 10 days with standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (Clr) (MAD Period Day 10)</title>
          <description>Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aeτ) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCτ), where dosing interval is 24 hours for QD dosing and 12 hours for BID dosing.</description>
          <population>The analysis population included healthy participants who received study treatment on Day 10 and who had the Day 10 PK parameters in the MAD Period. Data on the other days of MAD Period as well as in SAD and Psoriasis Cohorts were not included.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2928" spread="70"/>
                    <measurement group_id="O2" value="0.5500" spread="42"/>
                    <measurement group_id="O3" value="1.274" spread="39"/>
                    <measurement group_id="O4" value="0.5777" spread="34"/>
                    <measurement group_id="O5" value="0.4076" spread="500"/>
                    <measurement group_id="O6" value="0.9909" spread="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ (Psoriasis Cohorts)</title>
        <description>AUCτ was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ (Psoriasis Cohorts)</title>
          <description>AUCτ was summarized by dosing regimen and period. It was determined by linear/log trapezoidal method.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2401" spread="53"/>
                    <measurement group_id="O2" value="7664" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ(dn) (Psoriasis Cohorts)</title>
        <description>AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ(dn) (Psoriasis Cohorts)</title>
          <description>AUCτ(dn) = AUCτ / Dose. To assess the relationship between the PK parameters and the dose, dose normalized AUCτ was plotted against dose, and included individual participant values and the geometric means for each dose.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>ng*hr/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.01" spread="53"/>
                    <measurement group_id="O2" value="19.17" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax (Psoriasis Cohorts)</title>
        <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Psoriasis Cohorts)</title>
          <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296.6" spread="38"/>
                    <measurement group_id="O2" value="869.8" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax(dn) (Psoriasis Cohorts)</title>
        <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax(dn) (Psoriasis Cohorts)</title>
          <description>Cmax was summarized by dosing regimen and period. It was observed directly from data.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>ng/mL/mg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.966" spread="38"/>
                    <measurement group_id="O2" value="2.176" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax (Psoriasis Cohorts)</title>
        <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Psoriasis Cohorts)</title>
          <description>Tmax was summarized by dosing regimen and period. It was observed directly from data as time of first occurrence.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>hours (hr)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cav (Psoriasis Cohorts)</title>
        <description>Cav = AUCτ,ss / τ, where ss means 'at steady state'. Cav was summarized by dosing regimen and period.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cav (Psoriasis Cohorts)</title>
          <description>Cav = AUCτ,ss / τ, where ss means 'at steady state'. Cav was summarized by dosing regimen and period.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.2" spread="53"/>
                    <measurement group_id="O2" value="319.3" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmin (Psoriasis Cohorts)</title>
        <description>Cmin was observed directly from data. It was summarized by dosing regimen and period.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmin (Psoriasis Cohorts)</title>
          <description>Cmin was observed directly from data. It was summarized by dosing regimen and period.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.92" spread="103"/>
                    <measurement group_id="O2" value="38.12" spread="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life ((t½) (Psoriasis Cohorts)</title>
        <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life ((t½) (Psoriasis Cohorts)</title>
          <description>t1/2 was summarized by dosing regimen and period. It was determined by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear concentration time curve. Only those data points judged to describe the terminal log linear decline were used in the regression.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>hours (hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.796" spread="5.7087"/>
                    <measurement group_id="O2" value="6.809" spread="5.4050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRT (Psoriasis Cohorts)</title>
        <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24,168 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>MRT (Psoriasis Cohorts)</title>
          <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from time 0 to infinity.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>hours (hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27" spread="41"/>
                    <measurement group_id="O2" value="9.444" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTR (Psoriasis Cohorts)</title>
        <description>PTR = Cmax,ss / Cmin,ss, it was summarized by dosing regimen and period.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PTR (Psoriasis Cohorts)</title>
          <description>PTR = Cmax,ss / Cmin,ss, it was summarized by dosing regimen and period.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.52" spread="76"/>
                    <measurement group_id="O2" value="22.81" spread="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F (Psoriasis Cohorts)</title>
        <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F (Psoriasis Cohorts)</title>
          <description>Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.1" spread="30"/>
                    <measurement group_id="O2" value="461.2" spread="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F (Psoriasis Cohorts)</title>
        <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>Day 28 pre-dose, and 0.5,1,2,4,6,8,12,16,24 hours post-dose</time_frame>
        <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F (Psoriasis Cohorts)</title>
          <description>CL/F is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>The analysis population included psoriasis participants who received study treatment on Day 1 and who had the Day 1 PK parameters in the Psoriasis Cohorts. Data on the other days of Psoriasis Cohorts study treatment period, as well as in SAD/MAD Periods were not included.</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.61" spread="53"/>
                    <measurement group_id="O2" value="52.21" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 28</title>
        <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section*area score*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>The analysis population included psoriasis participants who received the 28-day study treatment and who had the efficacy parameters at Baseline and on Day 28 in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>PBO QD PSO</title>
            <description>In the psoriasis (PSO) cohorts, psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal.</description>
          </group>
          <group group_id="O2">
            <title>PF-06826647 400 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
          <group group_id="O3">
            <title>PF-06826647 100 mg QD PSO</title>
            <description>In this psoriasis cohort, psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Day 28</title>
          <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90-100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section*area score*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0= no disease to 72= maximal disease.</description>
          <population>The analysis population included psoriasis participants who received the 28-day study treatment and who had the efficacy parameters at Baseline and on Day 28 in the Psoriasis Cohorts. Data in SAD/MAD Periods were not included.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.13" spread="2.405"/>
                    <measurement group_id="O2" value="-24.18" spread="2.281"/>
                    <measurement group_id="O3" value="-14.62" spread="2.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Day 8 for SAD Cohorts, which included PF-06826647 3mg, 10mg, 30mg, 100mg, 400mg, and 1600mg SD cohorts as well as placebo matching each SAD cohort. Baseline up to Day 28 for MAD Cohorts, which included PF-06826647 30mg, 100mg, 400mg, 1200mg QD, 200mg BID, 400mg QD JP, as well as placebo matching each MAD cohort. Baseline up to Day 84 for Psoriasis Cohorts, which included PF-06826647 400mg and 100mg QD cohorts, as well as placebo matching each psoriasis cohort.</time_frame>
      <desc>The requirements for recording safety events on the CRF and for reporting safety events on the Clinical Trial Serious Adverse Event Report Form to Pfizer Safety were delineated for 3 types of events: (1) SAEs; (2) non-serious adverse events (AEs); and (3) exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo SAD</title>
          <description>During the SAD period (Period 1), the healthy participants received placebo matching PF-06826647 3, 10, 30, 100, 400, or 1600 mg cohort SD cohort in fasted state. SAD period duration was 8 days. (Those placebo participants matching 30, 100, 400, or 1600 SD cohort later continued into MAD period and received the placebo matching 30, 100, 400, or 1200 mg QD cohort, respectively.)</description>
        </group>
        <group group_id="E2">
          <title>Placebo QD MAD (JP Placebo Included)</title>
          <description>This arm includes both non-Japanese and Japanese participants. In MAD period (Period 2), the non-Japanese participants (they had completed the SAD period) received placebo matching PF-06826647 30, 100, 400, or 1200 mg QD cohort while the Japanese participants (they did not take part in SAD period) received placebo matching PF-06826647 400 mg QD Japanese cohort, both for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo BID</title>
          <description>Edit During the MAD period (Period 2), the healthy participants received placebo matching PF-06826647 200 mg BID cohort for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E4">
          <title>PF-06826647 3 mg SAD</title>
          <description>During the SAD period (Period 1), the healthy participants received PF-06826647 3 mg SD in fasted state. SAD period duration was 8 days.</description>
        </group>
        <group group_id="E5">
          <title>PF-06826647 10 mg SAD</title>
          <description>During the SAD period (Period 1), the healthy participants received PF-06826647 10 mg SD in fasted state. SAD period duration was 8 days.</description>
        </group>
        <group group_id="E6">
          <title>PF-06826647 30 mg SAD</title>
          <description>During the SAD period (Period 1), the healthy participants received PF-06826647 30 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 30 mg QD in MAD period.)</description>
        </group>
        <group group_id="E7">
          <title>PF-06826647 30 mg QD MAD</title>
          <description>During the MAD period (Period 2), the healthy participants who had taken PF-06826647 30 mg SD received PF-06826647 30 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E8">
          <title>PF-06826647 100 mg SAD</title>
          <description>During the SAD period (Period 1), the healthy participants received PF-06826647 100 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 100 mg QD in MAD period.)</description>
        </group>
        <group group_id="E9">
          <title>PF-06826647 100 mg QD MAD</title>
          <description>During the MAD period (Period 2), the healthy participants who had taken PF-06826647 100 mg SD received PF-06826647 100 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E10">
          <title>PF-06826647 400 mg SAD</title>
          <description>During the SAD period (Period 1), the healthy participants received PF-06826647 400 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 400 mg QD in MAD period.)</description>
        </group>
        <group group_id="E11">
          <title>PF-06826647 400 mg QD MAD</title>
          <description>During the MAD period (Period 2), the healthy participants who had taken PF-06826647 400 mg SD received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E12">
          <title>PF-06826647 1600 mg SAD</title>
          <description>During the SAD period (Period 1), the healthy participants received PF-06826647 1600 mg SD in fasted state. SAD period duration was 8 days. (These participants later continued into PF-06826647 1200 mg QD in MAD period.)</description>
        </group>
        <group group_id="E13">
          <title>PF-06826647 1200 mg QD MAD</title>
          <description>During the MAD period (Period 2), the healthy participants who had taken PF-06826647 1600 mg SD received PF-06826647 1200 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E14">
          <title>PF-06826647 200 mg BID</title>
          <description>During the MAD period (Period 2), the healthy participants received PF-06826647 200 mg BID for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E15">
          <title>PF-06826647 400 mg QD MAD JP</title>
          <description>During the MAD period (Period 2), the Japanese healthy participants received PF-06826647 400 mg QD for 10 days with standard meal. MAD period duration was 28 days.</description>
        </group>
        <group group_id="E16">
          <title>Placebo QD PSO</title>
          <description>In the psoriasis (PSO) cohorts, the psoriasis participants received placebo matching PF-06826647 400, or 100 mg QD PSO cohort for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
        </group>
        <group group_id="E17">
          <title>PF-06826647 400 mg QD PSO</title>
          <description>In this psoriasis cohort, the psoriasis participants received PF-06826647 400 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
        </group>
        <group group_id="E18">
          <title>PF-06826647 100 mg QD PSO</title>
          <description>In this psoriasis cohort, the psoriasis participants received PF-06826647 100 mg QD for 28 days with standard meal. Psoriasis cohort duration was 84 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E16" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E17" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Periorbital haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E17" events="5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E18" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Body temperature</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E16" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="4" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

